● Developing story
US drug pricing tracker: Medicare talks, MFN deals and TrumpRx
US drug pricing policy now runs on two tracks. Medicare's negotiated prices for the first 10 drugs took effect in 2026, and prices for 15 more, including Ozempic and Wegovy, start on 1 January 2027.[1][2] Alongside them, the White House says it has struck most-favored-nation (MFN) pricing deals with 26 drugmakers, launched the TrumpRx.gov cash-price site, tied pharmaceutical tariffs to those deals and finalised a Medicare model, GLOBE, that benchmarks Part B drug rebates to international prices.[3][4][5][6] Third-round negotiated prices are due by 30 November 2026.[7]
What we know
- Negotiated Medicare prices for the first 10 Part D drugs took effect on 1 January 2026[1]
- Negotiated prices for 15 more Part D drugs, including Ozempic and Wegovy, take effect on 1 January 2027[2]
- The White House says it has MFN agreements with 26 drugmakers covering 89% of the branded market (September 2026)[3]
- TrumpRx.gov launched on 5 February 2026 and added more than 600 generics on 18 May 2026[24]
- Patented drugs face a 100% Section 232 tariff, cut to 0% for companies with MFN and onshoring agreements[5]
- CMS finalised the mandatory GLOBE model; it starts on 1 January 2027[6]
- CMS finalised its rule codifying the negotiation programme on 9 November 2026; it takes effect on 5 December 2026[16]
- The GUARD model for Part D drugs was still only proposed as of 14 November 2026[28]
What we don't know yet
- The negotiated prices for the 15 third-cycle drugs, including the first Part B drugs, which CMS must publish by 30 November 2026
- Whether and when CMS finalises the GUARD model for Part D drugs
- The terms of the individual MFN agreements, which have not been published
- How much patients and programmes actually save; the savings figures published so far are the administration's own estimates
This tracker describes government policy and announced prices. It is not medical, legal or financial advice. Prices depend on your plan and prescription: check with your pharmacist, your plan or Medicare before making decisions, and talk to a clinician about any change to a medicine.
Two tracks: negotiation and MFN deals
Since 2025 federal drug pricing policy has moved on two tracks. The first is the Medicare Drug Price Negotiation Program created by the Inflation Reduction Act. Under it, CMS negotiates prices directly for certain high-spending drugs that lack generic or biosimilar competition.[8] The second is a set of most-favored-nation (MFN) actions. Executive Order 14297, signed on 12 May 2025, directed HHS to give drugmakers price targets in line with prices in comparable developed countries within 30 days, and to propose rules imposing MFN pricing if they did not make significant progress.[9] The order said the United States, with less than 5% of the world’s population, funds around three quarters of global pharmaceutical profits.[10] The background is in the medicare-drug-price-negotiation entry and the Medicare 2027 explainer.[11]
Medicare negotiated prices
Negotiated prices for the first 10 Part D drugs, including Eliquis, Jardiance and Xarelto, took effect on 1 January 2026.[1] CMS estimated that these prices would have saved Medicare $6 billion, or 22% net, had they applied in 2023.[12] In the second cycle Medicare reached agreement on all 15 selected drugs, including Ozempic and Wegovy. Those prices take effect on 1 January 2027.[2] The negotiated 30-day price for Ozempic, Rybelsus and Wegovy is $274, against a 2024 list price of $959.[13]
On 27 January 2026 CMS chose 15 drugs for the third cycle, including the first Part B drugs, with prices effective from 1 January 2028.[14] Every manufacturer agreed to take part.[8] Companies had to accept or reject CMS’s final offers by 31 October 2026, and CMS must publish the prices by 30 November 2026.[7] In June 2026 CMS also proposed a rule to write the programme into regulation.[15] It published the final rule on 9 November 2026, and the regulations take effect on 5 December 2026.[16] The 2025 reconciliation law widened the exclusion for orphan drugs, which KFF says delayed the selection of Keytruda and Opdivo.[17]
MFN agreements with drugmakers
On 31 July 2025 the President sent letters to 17 drugmakers. The letters asked for MFN prices in Medicaid, matching prices for new drugs and direct sales to patients.[18] Pfizer signed the first agreement on 30 September 2025.[19] Agreements with Eli Lilly and Novo Nordisk announced by the White House in November 2025 set Medicare prices of $245 a month for their GLP-1 drugs and a $50 copay.[20] Nine more companies signed on 19 December 2025.[21] By 18 September 2026 the White House counted 26 companies with agreements, covering what it said was 89% of the branded drug market. The terms of the individual agreements have not been published.[3]
In Medicaid, the White House said in September 2026 that all 50 state programmes would get MFN-level prices through rebates under the GENEROUS model. The White House Council of Economic Advisers estimated $64.3 billion in savings over a decade.[22]
TrumpRx.gov and tariffs
TrumpRx.gov launched on 5 February 2026 with cash prices on about 40 branded medicines from the first five companies with deals.[4] The White House said Ozempic and injectable Wegovy would average $350 a month there and the Wegovy pill would start at $149.[23] In May 2026 the site added cash prices for more than 600 generics, with discounts from Amazon Pharmacy, Cost Plus Drugs and GoodRx.[24] The administration says patients saved more than $700 million there by September 2026; that figure is its own estimate.[25] For older adults, Medicare’s GLP-1 Bridge has offered certain GLP-1 drugs for $50 a month since 1 July 2026; the GLP-1 access and pricing debate covers the wider argument.[26]
Trade policy is tied to the deals. On 2 April 2026 the President imposed a 100% Section 232 tariff on patented drugs and their ingredients. Companies with both MFN and onshoring agreements pay 0% through 20 January 2029, and generics and biosimilars are exempt for now.[5]
New Medicare models: GLOBE and GUARD
In December 2025 CMS proposed two models that recalculate drugmakers’ inflation rebates using international prices. GLOBE covers certain Part B drugs and GUARD certain Part D drugs.[27] CMS finalised GLOBE as a mandatory model on 2 October 2026. It starts on 1 January 2027, and its five performance years run from April 2027 to March 2032.[6] GUARD was proposed to run from 2027 to 2033, but as of 14 November 2026 the Federal Register still listed it only as a proposed rule.[28] How new drugs reach the market in the first place is explained in how FDA drug approval works.[29]
Pending: third-cycle negotiated prices (due by 30 November 2026), second-cycle prices and the GLOBE model start (1 January 2027), and any final GUARD rule. This tracker will be updated as each lands.
Timeline
18 confirmed
confirmed
CMS finalises the rule codifying the negotiation programme[16]
confirmed
CMS finalises the mandatory GLOBE model[6]
confirmed
White House says all 50 state Medicaid programmes get MFN prices through the GENEROUS model[22][25]
confirmed
Nine more MFN agreements bring the total to 26 companies[3]
confirmed
Medicare GLP-1 Bridge begins at $50 a month[26]
confirmed
CMS proposes a rule to codify the negotiation programme[15]
confirmed
TrumpRx.gov adds more than 600 generic medicines[24]
confirmed
Section 232 tariffs on patented drugs, waived for companies with MFN and onshoring deals[5]
confirmed
All third-cycle drugmakers agree to take part in negotiation[8]
confirmed
TrumpRx.gov launches[4][23]
confirmed
CMS selects 15 drugs for the third negotiation cycle, including the first Part B drugs[14]
confirmed
First Medicare negotiated prices take effect[1][12]
confirmed
CMS proposes the GLOBE and GUARD international-pricing models[27]
confirmed
Nine more drugmakers sign MFN agreements[21]
confirmed
Eli Lilly and Novo Nordisk agree MFN prices for GLP-1 drugs[20][30]
confirmed
Pfizer signs the first MFN agreement[19]
confirmed
White House sends MFN letters to 17 drugmakers[18]
confirmed
Executive Order 14297 orders most-favored-nation drug pricing[9][10]
Read next
Medicare Drug Price Negotiation Program
How Medicare negotiates drug prices: the 10 drugs priced from 2026, 15 from 2027 including Ozempic, the 2028 list with first Part B drugs, and what is next.
Questions readers ask
What is Medicare drug price negotiation?
Under the Inflation Reduction Act, CMS negotiates prices for certain high-spending drugs that have no generic or biosimilar competition. The first 10 negotiated prices took effect on 1 January 2026, and 15 more take effect on 1 January 2027.[8][1][2]
What is a most-favored-nation (MFN) drug price?
It is a price in line with what comparably developed nations pay. A May 2025 executive order directed HHS to set MFN price targets for drugmakers, and the White House has since announced agreements with 26 companies.[9][3]
What is TrumpRx.gov?
It is a federal website, launched on 5 February 2026, that lists discounted cash prices for branded drugs from companies with MFN deals. Since May 2026 it has also listed cash prices for more than 600 generics.[4][24]
How much does Ozempic cost through TrumpRx or Medicare?
At launch the White House said TrumpRx prices for Ozempic and injectable Wegovy would average $350 a month. Separately, Medicare's negotiated 30-day price for Ozempic, Rybelsus and Wegovy is $274 from 1 January 2027.[23][13]
What are the GLOBE and GUARD models?
They are Medicare payment models that change how drugmakers' inflation rebates are calculated using international prices, GLOBE for certain Part B drugs and GUARD for certain Part D drugs. CMS finalised GLOBE in October 2026 to start in January 2027. GUARD was still a proposal as of 14 November 2026.[27][6][28]
Sources
· 30 claims from 11 publishers
Each numbered claim is a statement we checked against the sources listed with it. Tap a number in the text to see its sources in place.
- [1]
Medicare's negotiated prices for the first 10 Part D drugs, including Eliquis, Jardiance, Xarelto, Januvia, Farxiga, Entresto, Enbrel, Imbruvica, Stelara and Fiasp/NovoLog, took effect on 1 January 2026. confirmedas of 2026-03-11
- Key Facts About Medicare Drug Price Negotiation · KFF · Secondary source · 2026-03-11 · Selected Drugs for Implementation Year 2026 (retrieved 2026-10-11)
- Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026 · U.S. Centers for Medicare & Medicaid Services · Primary source · 2024-08-15 · Fact sheet lists negotiated prices for 10 drugs covered under Medicare Part D (retrieved 2026-10-11)
- [2]
In the second cycle Medicare reached agreement on all 15 selected Part D drugs, including Ozempic and Wegovy; the prices take effect on 1 January 2027, and CMS estimated they would have saved about $8.5 billion (about 36% lower net spending) had they applied in 2024. confirmedas of 2026-01-27
- CMS Announces Selection of Drugs for Third Cycle of Medicare Drug Price Negotiation Program, Including First-Ever Part B Drugs · U.S. Centers for Medicare & Medicaid Services · Primary source · 2026-01-27 · Also: "saved an estimated $8.5 billion in net covered prescription drug costs ... approximately 36% lower net spending" (retrieved 2026-10-11)
- [3]
As of 18 September 2026 the White House said it had MFN agreements with 26 drugmakers covering 89% of the branded drug market, including nine announced on 31 August 2026. confirmedas of 2026-09-18
- Fact Sheet: President Donald J. Trump Announces Lower Drug Prices for All 50 State Medicaid Programs · The White House · Primary source · 2026-09-18 (retrieved 2026-11-07)
- Fact Sheet: President Donald J. Trump Announces Lower Drug Prices for All 50 State Medicaid Programs · The White House · Primary source · 2026-09-18 (retrieved 2026-11-07)
- [4]
TrumpRx.gov launched on 5 February 2026 with discounted cash prices on about 40 branded medicines from the first five companies with MFN deals, AstraZeneca, Eli Lilly, EMD Serono, Novo Nordisk and Pfizer. confirmedas of 2026-02-05
- Fact Sheet: President Donald J. Trump Launches TrumpRx.gov to Bring Lower Drug Prices to American Patients · The White House · Primary source · 2026-02-05 (retrieved 2026-11-07)
- Fact Sheet: President Donald J. Trump Launches TrumpRx.gov to Bring Lower Drug Prices to American Patients · The White House · Primary source · 2026-02-05 (retrieved 2026-11-07)
- [5]
On 2 April 2026 the President imposed Section 232 tariffs of 100% on patented pharmaceutical products and ingredients, with 15% for products from the EU, Japan, Korea and Switzerland and Liechtenstein, 0% through 20 January 2029 for companies with both MFN pricing and onshoring agreements, and generics and biosimilars exempt for now. confirmedas of 2026-04-02
- Fact Sheet: President Donald J. Trump Bolsters National Security and Strengthens U.S. Supply Chains by Imposing Tariffs on Patented Pharmaceutical Products · The White House · Primary source · 2026-04-02 (retrieved 2026-11-07)
- Fact Sheet: President Donald J. Trump Bolsters National Security and Strengthens U.S. Supply Chains by Imposing Tariffs on Patented Pharmaceutical Products · The White House · Primary source · 2026-04-02 (retrieved 2026-11-07)
- Fact Sheet: President Donald J. Trump Bolsters National Security and Strengthens U.S. Supply Chains by Imposing Tariffs on Patented Pharmaceutical Products · The White House · Primary source · 2026-04-02 (retrieved 2026-11-07)
- Fact Sheet: President Donald J. Trump Bolsters National Security and Strengthens U.S. Supply Chains by Imposing Tariffs on Patented Pharmaceutical Products · The White House · Primary source · 2026-04-02 (retrieved 2026-11-07)
- [6]
CMS finalised the GLOBE model as a mandatory Medicare model in a rule published on 2 October 2026 and effective 30 November 2026; it starts on 1 January 2027 with voluntary submission of international net price data and runs five performance years from 1 April 2027 to 31 March 2032. confirmedas of 2026-10-02
- Global Benchmark for Efficient Drug Pricing (GLOBE) Model (final rule) · Federal Register (Centers for Medicare & Medicaid Services) · Primary source · 2026-10-02 (retrieved 2026-11-07)
- Global Benchmark for Efficient Drug Pricing (GLOBE) Model (final rule) · Federal Register (Centers for Medicare & Medicaid Services) · Primary source · 2026-10-02 (retrieved 2026-11-07)
- Global Benchmark for Efficient Drug Pricing (GLOBE) Model (final rule) · Federal Register (Centers for Medicare & Medicaid Services) · Primary source · 2026-10-02 (retrieved 2026-11-07)
- [7]
For the third cycle, CMS's final written offers were due by 30 September 2026, drug companies must accept or reject them by 31 October 2026, the negotiation period ends on 1 November 2026, and CMS must publish negotiated prices by 30 November 2026. confirmedas of 2026-03-11
- Key Facts About Medicare Drug Price Negotiation · KFF · Secondary source · 2026-03-11 · Timeline: final offer "no later than September 30, 2026"; acceptance or rejection "by October 31, 2026" (retrieved 2026-10-11)
- Key Facts About Medicare Drug Price Negotiation · KFF · Secondary source · 2026-03-11 · Negotiation process steps (retrieved 2026-10-11)
- Key Facts About Medicare Drug Price Negotiation · KFF · Secondary source · 2026-03-11 · Negotiation process steps (retrieved 2026-10-11)
- Medicare Drug Price Negotiation Program: Selected Drugs for Initial Price Applicability Year 2028 (fact sheet) · U.S. Centers for Medicare & Medicaid Services · Primary source · 2026-01-27 · Timeline: "September 30, 2026 -- Deadline for CMS to send a final MFP offer"; "October 31, 2026 -- Deadline for participating drug companies to accept or reject a final MFP offer"; "November 1, 2026 -- The negotiation and renegotiation period ends." (retrieved 2026-10-11)
- [8]
Under the Negotiation Program CMS directly negotiates prices of certain high-expenditure, single-source drugs without generic or biosimilar competition; on 13 March 2026 it announced that the manufacturers of all 15 third-cycle drugs, and of the drug selected for renegotiation, chose to participate. confirmedas of 2026-03-13
- CMS Announces Manufacturer Participation in Third Cycle of Medicare Drug Price Negotiation · U.S. Centers for Medicare & Medicaid Services · Primary source · 2026-03-13 · Opening: "CMS directly negotiates the prices of certain high expenditure, single source drugs without generic or biosimilar competition" (retrieved 2026-10-11)
- [9]
Executive Order 14297, signed on 12 May 2025, directed HHS to communicate most-favored-nation (MFN) price targets to drugmakers within 30 days and, if significant progress was not made, to propose rulemaking to impose MFN pricing and consider other steps such as drug importation. confirmedas of 2025-05-15
- Executive Order 14297: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients · Federal Register · Primary source · 2025-05-15 (retrieved 2026-11-07)
- Executive Order 14297: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients · Federal Register · Primary source · 2025-05-15 (retrieved 2026-11-07)
- Executive Order 14297: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients · Federal Register · Primary source · 2025-05-15 (retrieved 2026-11-07)
- Executive Order 14297: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients · Federal Register · Primary source · 2025-05-15 (retrieved 2026-11-07)
- [10]
The executive order asserted that the United States, with less than 5% of the world's population, funds around three quarters of global pharmaceutical profits. confirmedas of 2025-05-15
- Executive Order 14297: Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients · Federal Register · Primary source · 2025-05-15 (retrieved 2026-11-07)
- [11]
Under the Inflation Reduction Act, up to 20 drugs are selected for negotiation for each price year from 2029 on, with selection starting in 2027. confirmedas of 2026-03-11
- Key Facts About Medicare Drug Price Negotiation · KFF · Secondary source · 2026-03-11 (retrieved 2026-10-11)
- Public Law 117-169 (Inflation Reduction Act of 2022) · U.S. Government Publishing Office (public law text) · Primary source · 2022-08-16 · Sec. 11001, new SSA sec. 1192(a)(4) (retrieved 2026-10-11)
- [12]
CMS estimated Medicare would have saved $6 billion, or 22% net, if the first-round negotiated prices had applied in 2023. confirmedas of 2026-03-11
- Key Facts About Medicare Drug Price Negotiation · KFF · Secondary source · 2026-03-11 (retrieved 2026-10-11)
- Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2026 · U.S. Centers for Medicare & Medicaid Services · Primary source · 2024-08-15 (retrieved 2026-10-11)
- [13]
Under the Medicare Drug Price Negotiation Program, CMS set a negotiated 30-day price of $274 for Ozempic, Rybelsus and Wegovy, against a 2024 list price of $959, effective 1 January 2027. confirmedas of 2025-11-25
- Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027 (fact sheet) · Centers for Medicare & Medicaid Services · Primary source · 2025-11-25 · Q&A and price table (Ozempic; Rybelsus; Wegovy, list price $959) (retrieved 2026-10-10)
- Medicare Drug Price Negotiation Program: Negotiated Prices for Initial Price Applicability Year 2027 (fact sheet) · Centers for Medicare & Medicaid Services · Primary source · 2025-11-25 · Price table, row "Ozempic; Rybelsus; Wegovy": negotiated 30-day price, 2024 list price, discount (PDF table; check by hand) (retrieved 2026-10-10)
- [14]
On 27 January 2026 CMS selected 15 drugs for the third cycle, including the first Part B drugs, with prices effective 1 January 2028; the list is Anoro Ellipta, Biktarvy, Botox, Cimzia, Cosentyx, Entyvio, Erleada, Kisqali, Lenvima, Orencia, Rexulti, Trulicity, Verzenio, Xeljanz and Xolair, and Tradjenta was picked for renegotiation. confirmedas of 2026-01-27
- CMS Announces Selection of Drugs for Third Cycle of Medicare Drug Price Negotiation Program, Including First-Ever Part B Drugs · U.S. Centers for Medicare & Medicaid Services · Primary source · 2026-01-27 · Selected drug list and renegotiation (Tradjenta) (retrieved 2026-10-11)
- [15]
On 16 June 2026 CMS proposed a rule to codify the Medicare Drug Price Negotiation Program created by the Inflation Reduction Act, with comments due by 17 August 2026. confirmedas of 2026-06-16
- Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program (proposed rule) · Federal Register (Centers for Medicare & Medicaid Services) · Primary source · 2026-06-16 · Comment deadline of 17 August 2026 from the Federal Register document metadata (comments_close_on). (retrieved 2026-11-07)
- Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program (proposed rule) · Federal Register (Centers for Medicare & Medicaid Services) · Primary source · 2026-06-16 (retrieved 2026-11-07)
- [16]
CMS published a final rule on 9 November 2026 that finalizes and codifies the Medicare Drug Price Negotiation Program and sets new policies for it and for the Part D program; the regulations take effect on 5 December 2026. confirmedas of 2026-11-09
- Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program (final rule) · Federal Register (Centers for Medicare & Medicaid Services) · Primary source · 2026-11-09 (retrieved 2026-11-14)
- Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program (final rule) · Federal Register (Centers for Medicare & Medicaid Services) · Primary source · 2026-11-09 (retrieved 2026-11-14)
- [17]
The 2025 reconciliation law broadened the orphan-drug exclusion from negotiation to drugs approved for one or more rare diseases, applying from the 2028 price year; KFF says this delayed selection of Keytruda and Opdivo beyond 2026. confirmedas of 2026-03-11
- Key Facts About Medicare Drug Price Negotiation · KFF · Secondary source · 2026-03-11 · Orphan drug exclusion section (retrieved 2026-10-11)
- Public Law 119-21 (H.R. 1), the 2025 budget reconciliation law · U.S. Government Publishing Office (public law text) · Primary source · 2025-07-04 · Body strikes "only one rare disease or condition" and inserts "one or more rare diseases or conditions"; applies to price years beginning on or after January 1, 2028 (retrieved 2026-10-11)
- [18]
On 31 July 2025 the President sent letters to 17 drugmakers (AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, Gilead, GSK, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Regeneron and Sanofi) setting out steps to reach MFN prices, including MFN prices for Medicaid and direct sales to patients. confirmedas of 2025-07-31
- Fact Sheet: President Donald J. Trump Announces Actions to Get Americans the Best Prices in the World for Prescription Drugs · The White House · Primary source · 2025-07-31 (retrieved 2026-11-07)
- Fact Sheet: President Donald J. Trump Announces Actions to Get Americans the Best Prices in the World for Prescription Drugs · The White House · Primary source · 2025-07-31 (retrieved 2026-11-07)
- Unpacking the Federal Drug Price Reduction Struggle · Leonard Davis Institute of Health Economics, University of Pennsylvania · Secondary source · 2026-01-22 (retrieved 2026-11-07)
- [19]
On 30 September 2025 the White House announced the first MFN agreement, with Pfizer, under which Pfizer would give state Medicaid programs MFN prices, guarantee MFN prices on new medicines and sell directly to patients at a discount. confirmedas of 2025-09-30
- Fact Sheet: President Donald J. Trump Announces First Deal to Bring Most-Favored-Nation Pricing to American Patients · The White House · Primary source · 2025-09-30 (retrieved 2026-11-07)
- Fact Sheet: President Donald J. Trump Announces First Deal to Bring Most-Favored-Nation Pricing to American Patients · The White House · Primary source · 2025-09-30 (retrieved 2026-11-07)
- Unpacking the Federal Drug Price Reduction Struggle · Leonard Davis Institute of Health Economics, University of Pennsylvania · Secondary source · 2026-01-22 (retrieved 2026-11-07)
- [20]
Under a 6 November 2025 agreement announced by the White House with Eli Lilly and Novo Nordisk, Medicare prices for Ozempic, Wegovy, Mounjaro and Zepbound were set at $245 a month with a $50 monthly copay for beneficiaries, and Ozempic and Wegovy at $350 through the TrumpRx website. confirmedas of 2025-11-06
- Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients · The White House · Primary source · 2025-11-06 (retrieved 2026-10-10)
- Novo, Lilly cut deal with Trump to lower prices of obesity drugs · Healthcare Dive · Secondary source · 2025-11-06 (retrieved 2026-10-10)
- [21]
On 19 December 2025 the White House announced MFN agreements with nine more drugmakers, Amgen, Bristol Myers Squibb, Boehringer Ingelheim, Genentech, Gilead Sciences, GSK, Merck, Novartis and Sanofi, citing examples such as a TrumpRx price for Amgen's Repatha of $239, down from $573. confirmedas of 2025-12-19
- Fact Sheet: President Donald J. Trump Announces Largest Developments to Date in Bringing Most-Favored-Nation Pricing to American Patients · The White House · Primary source · 2025-12-19 (retrieved 2026-11-07)
- Fact Sheet: President Donald J. Trump Announces Largest Developments to Date in Bringing Most-Favored-Nation Pricing to American Patients · The White House · Primary source · 2025-12-19 (retrieved 2026-11-07)
- Federal Update: Trump Admin Unveils GLOBE, GUARD Models, Plus Nine Additional MFN Arrangements · Academy of Managed Care Pharmacy (AMCP) · Secondary source (retrieved 2026-11-07)
- [22]
On 18 September 2026 the White House said all 50 state Medicaid programs would get MFN-level prices through the GENEROUS Medicaid payment model, in which participating drugmakers pay rebates so Medicaid's final price does not exceed the MFN price; the Council of Economic Advisers estimated $64.3 billion in savings over a decade. confirmedas of 2026-09-18
- Fact Sheet: President Donald J. Trump Announces Lower Drug Prices for All 50 State Medicaid Programs · The White House · Primary source · 2026-09-18 (retrieved 2026-11-07)
- Fact Sheet: President Donald J. Trump Announces Lower Drug Prices for All 50 State Medicaid Programs · The White House · Primary source · 2026-09-18 (retrieved 2026-11-07)
- [23]
At launch the White House said TrumpRx monthly prices for Ozempic and injectable Wegovy would average $350 (from $1,028 and $1,349 list), the Wegovy pill would start at $149, and Zepbound would average $346. confirmedas of 2026-02-05
- Fact Sheet: President Donald J. Trump Launches TrumpRx.gov to Bring Lower Drug Prices to American Patients · The White House · Primary source · 2026-02-05 (retrieved 2026-11-07)
- Fact Sheet: President Donald J. Trump Launches TrumpRx.gov to Bring Lower Drug Prices to American Patients · The White House · Primary source · 2026-02-05 (retrieved 2026-11-07)
- Fact Sheet: President Donald J. Trump Launches TrumpRx.gov to Bring Lower Drug Prices to American Patients · The White House · Primary source · 2026-02-05 (retrieved 2026-11-07)
- [24]
On 18 May 2026 TrumpRx.gov added cash prices for more than 600 generic medicines, integrating discounts from Amazon Pharmacy, Cost Plus Drugs and GoodRx, listed separately from the MFN brand-name discounts. confirmedas of 2026-05-18
- Fact Sheet: President Donald J. Trump Announces Expansion of TrumpRx.gov to Bring Americans Transparency and Choice on Everyday Medicines · The White House · Primary source · 2026-05-18 (retrieved 2026-11-07)
- Fact Sheet: President Donald J. Trump Announces Expansion of TrumpRx.gov to Bring Americans Transparency and Choice on Everyday Medicines · The White House · Primary source · 2026-05-18 (retrieved 2026-11-07)
- [25]
The White House said in September 2026 that patients had saved more than $700 million through TrumpRx.gov since its launch; the figure is the administration's own estimate. confirmedas of 2026-09-18
- Fact Sheet: President Donald J. Trump Announces Lower Drug Prices for All 50 State Medicaid Programs · The White House · Primary source · 2026-09-18 (retrieved 2026-11-07)
- [26]
CMS's Medicare GLP-1 Bridge, a time-limited demonstration, gives eligible Part D enrollees certain GLP-1 medicines for $50 a month from 1 July 2026 through 31 December 2027. confirmedas of 2026-05-06
- Coming Soon: CMS to Provide $50 Monthly Access to GLP-1 Medications for Medicare Beneficiaries · Centers for Medicare & Medicaid Services · Primary source · 2026-05-06 · Press release (program dates and $50 monthly supply) (retrieved 2026-10-10)
- [27]
In December 2025 CMS proposed two Medicare payment models tied to international prices, GLOBE for certain Part B drugs and GUARD for certain Part D drugs, each changing how manufacturers' inflation rebates are calculated; comments closed on 23 February 2026. confirmedas of 2025-12-23
- Global Benchmark for Efficient Drug Pricing (GLOBE) Model (proposed rule) · Federal Register (Centers for Medicare & Medicaid Services) · Primary source · 2025-12-23 (retrieved 2026-11-07)
- Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model (proposed rule) · Federal Register (Centers for Medicare & Medicaid Services) · Primary source · 2025-12-23 (retrieved 2026-11-07)
- Federal Update: Trump Admin Unveils GLOBE, GUARD Models, Plus Nine Additional MFN Arrangements · Academy of Managed Care Pharmacy (AMCP) · Secondary source (retrieved 2026-11-07)
- [28]
CMS proposed that the GUARD model's performance period run from 1 January 2027 to 31 December 2033; as of 14 November 2026 the Federal Register still listed GUARD only as a proposed rule. confirmedas of 2026-11-14
- Guarding U.S. Medicare Against Rising Drug Costs (GUARD) Model (proposed rule) · Federal Register (Centers for Medicare & Medicaid Services) · Primary source · 2025-12-23 · Status checked through the Federal Register documents API (term "GUARD Model", CMS documents) on 2026-11-14; only the 23 December 2025 proposed rule and the GLOBE final rule were listed. (retrieved 2026-11-07)
- [29]
To market a new drug, a developer files a New Drug Application containing everything from preclinical data to Phase 3 results; once FDA accepts the application as complete, its review team has 6 to 10 months to decide whether to approve. confirmedas of 2026-11-07
- Step 4: FDA Drug Review · US Food and Drug Administration · Primary source · New Drug Application (retrieved 2026-11-07)
- Step 4: FDA Drug Review · US Food and Drug Administration · Primary source · FDA Review (retrieved 2026-11-07)
- [30]
The November 2025 agreement set the starting dose of future oral GLP-1 drugs from the two companies at about $150 a month through TrumpRx. confirmedas of 2025-11-06
- Fact Sheet: President Donald J. Trump Announces Major Developments in Bringing Most-Favored-Nation Pricing to American Patients · The White House · Primary source · 2025-11-06 (retrieved 2026-10-10)
- Novo, Lilly cut deal with Trump to lower prices of obesity drugs · Healthcare Dive · Secondary source · 2025-11-06 (retrieved 2026-10-10)
Revision history (2)
Created Nov 7, 2026. Last reviewed by an editor on Nov 8, 2026. Next scheduled review: Dec 1, 2026.
Cite this page
"US drug pricing tracker: Medicare talks, MFN deals and TrumpRx." ContentLora, updated Nov 14, 2026. https://contentlora.com/events/us-drug-pricing-policy-tracker
Spotted an error? Suggest a correction or emailcorrections@contentlora.com.